What makes us different.
TD2’s integrated suite of preclinical services provides our clients with data that drives the development of clinical strategy. From the discovery stage to NDA strategy, we offer our clients advanced solutions to move their programs forward.
Our comprehensive service offerings utilized to rapidly move your treatments to the clinic include DMPK/ADME, in vitro and in vivo pharmacology, expert study design and execution. Your in vivo pharmacology studies are run in our AAALAC-accredited rodent facility with the highest regard for animal welfare. All studies are conducted with a commitment to meeting the high-quality standards you expect, and each offering is customizable to meet your unique development needs. With expert drug development insight and strategy and skilled project management, TD2 is your partner for an efficient path to the clinic.
Models and Services
TD2’s service offering is consistently expanding and currently includes:
Trusted IO Models
TD2 is your trusted, experienced team when it comes to running your preclinical immuno-oncology studies. We offer a comprehensive panel of human and murine tumor models to allow for planning and execution of studies in solid or hematologic malignancies. Our syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors. TD2’s vast experience in Adoptive Cell Transfer Therapy studies in both solid and hematologic tumors provide rapid, trusted study outcomes. When syngeneic mouse systems are not applicable for your drug, we can employee the use of humanized mice either by engrafting with human PBMCs or other effector cells or utilizing sourced CD34+ humanized mice.